{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["111(7)"],"submitter":["Osawa T"],"pubmed_abstract":["The present study aimed to evaluate the efficacy of the real-world use of axitinib and to develop a prognostic model for stratifying patients who could derive long-term benefit from axitinib. This was a retrospective, descriptive study evaluating the efficacy of axitinib in patients with metastatic renal cell carcinoma that had been treated with 1 or 2 systemic antiangiogenic therapy regimens at 1 of 36 hospitals belonging to the Japan Urologic Oncology Group between January 2012 and February 2019. The primary outcome was overall survival (OS). Using a split-sample method, candidate variables that exhibited significant relationships with OS were chosen to create a model. The new model was validated using the rest of the cohort. In total, 485 patients were enrolled. The median OS was 34 mon"],"journal":["Cancer science"],"pagination":["2460-2471"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7385391"],"repository":["biostudies-literature"],"pubmed_title":["Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma."],"pmcid":["PMC7385391"],"pubmed_authors":["Osawa T","Suzuki T","Morita K","Nishiyama H","Japanese Urological Oncology Group","Tamura K","Uemura M","Mitsuzuka K","Tomida R","Goto T","Shinohara N","Anai S","Minami K","Takeuchi A","Ueda K","Miyauchi Y","Hara T","Ohba K","Kusakabe N","Murakami M","Ito YM","Kashiwagi A","Sugimoto M","Murai S","Inoue T","Kojima T","Sazuka T","Nakai Y","Ozawa M","Ikeshiro S","Yasumoto H","Iwamoto H","Yamada S","Shimazui T","Shindo T","Yokomizo A","Kitamura H","Komiyama M","Nakagomi H","Eto M","Kohei N","Yamamoto Y","Morooka D","Mochizuki T"],"additional_accession":[]},"is_claimable":false,"name":"Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma.","description":"The present study aimed to evaluate the efficacy of the real-world use of axitinib and to develop a prognostic model for stratifying patients who could derive long-term benefit from axitinib. This was a retrospective, descriptive study evaluating the efficacy of axitinib in patients with metastatic renal cell carcinoma that had been treated with 1 or 2 systemic antiangiogenic therapy regimens at 1 of 36 hospitals belonging to the Japan Urologic Oncology Group between January 2012 and February 2019. The primary outcome was overall survival (OS). Using a split-sample method, candidate variables that exhibited significant relationships with OS were chosen to create a model. The new model was validated using the rest of the cohort. In total, 485 patients were enrolled. The median OS was 34 mon","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jul","modification":"2025-04-04T07:40:45.788Z","creation":"2025-04-04T07:40:45.788Z"},"accession":"S-EPMC7385391","cross_references":{"pubmed":["32402135"],"doi":["10.1111/cas.14449"]}}